{"name":"XBiotech","slug":"xbiotech","ticker":"XBIT","exchange":"NASDAQ","domain":"xbiotech.com","description":"XBiotech Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas. It specializes in the research and development of human-derived antibody therapeutics for multiple diseases, including cancer, rheumatological, and infectious diseases.","hq":"Austin, TX","founded":0,"employees":"","ceo":"John Simard","sector":"Immunology / Dermatology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$145M","metrics":{"revenue":1200000,"revenueGrowth":0,"grossMargin":0,"rdSpend":47390000,"netIncome":-45540000,"cash":125551000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Hutrukin","genericName":"Hutrukin","slug":"hutrukin","indication":"Other","status":"phase_1"},{"name":"Natrunix","genericName":"Natrunix","slug":"natrunix","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Hutrukin","genericName":"Hutrukin","slug":"hutrukin","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Natrunix","genericName":"Natrunix","slug":"natrunix","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"XBiotech Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"XBiotech reported its financial results for the fourth quarter and full year 2023, with a net loss of $13.4 million and $54.1 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"XBiotech Announces Collaboration with University of Texas to Develop New Antibody Therapies","summary":"XBiotech has entered into a collaboration with the University of Texas to develop new antibody therapies for the treatment of various diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-13","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-19","type":"pipeline","source":"simplywall.st","summary":"3 Promising Penny Stocks With Market Caps Over $30M - simplywall.st","headline":"3 Promising Penny Stocks With Market Caps Over $30M","sentiment":"neutral"},{"date":"2025-12-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-10-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-09-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-08-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBOdkRCMEs4YTdnTm8yeFNNeG15NmltZU5hQjROTXl3T0tSMnBINUMySTlDUW4zZnNBTG8yUUQ5S3lLajhuRXNGTW9VcWliNzE1Zy1j?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"XBIT Stock Price, News & Analysis - Stock Titan","headline":"XBIT Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxObWZMejV6TGJfUm9DZHRNUE9xcDVZNXZLc0d1d2NEMFBzVW44ZXN2YzFvenlNd3pKbDFacDBtcjd1ZnlFSnlWTjdxWVV4M1BqLW9XdXEtVzhtMHVKc2UxZEhDZVB4Y1FQd2lPeklsb25wSmFxU1NUdEZxbjA4MXRtRlpfMGJYWGV2OHZ1cQ?oc=5","date":"2024-12-23","type":"trial","source":"Stock Titan","summary":"XBiotech Halts Rheumatology Program After Major Data Irregularities Found in Phase 2 Trial - Stock Titan","headline":"XBiotech Halts Rheumatology Program After Major Data Irregularities Found in Phase 2 Trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNSlZySGt2VHJsVDExb1JHZ0tMWVFDb3NwSjQ5Mm1vc1ZJLXJOV3FHSnBueXJ5MGdXRWJoclM4QzR3Znk5bUp3MzJ5M3NxNzlkNUQxZ0tqZGdidWVfbHdsUGNuSlc1MlV6YkQyUHhYOWM2R3VEMFVHcmdLQS1oYTY1RUxaRmxSeGpjX2JYZ2Y2bkFwMnZERnlkUDItSmJCcUpTU0s0V2J6RQ?oc=5","date":"2024-05-24","type":"pipeline","source":"Seeking Alpha","summary":"XBiotech: Several Shots On Goal In Big Target Market Indications (NASDAQ:XBIT) - Seeking Alpha","headline":"XBiotech: Several Shots On Goal In Big Target Market Indications (NASDAQ:XBIT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPdFlFdnc0MDlPX0NURHZRQ0puSkV0ck14MEM2dGtyaHJBajA4U09zZkZhV21WSU1zNU9qTWhsdUFvSzlZM2tYaDZqY0NFZDhLTm5taUs2TGY1bkVpcllESDl1OGdRWFZhNDVoUFF6X0lJdGZqdW5HQVFZWFVoR3ZPVDFNQjJ6anY1dmRQSVNuWk5mTk1YaUZnM1N2WUxROVFuQk9FQzJCTnBEdXM?oc=5","date":"2022-02-02","type":"pipeline","source":"Reuters","summary":"J&J to record $610 mln charge related to skin disease drug - Reuters","headline":"J&J to record $610 mln charge related to skin disease drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQbU9ELXpYRmJ2bVl0eEZhT2N0QXVxRFpremYtZ2MtdThqRjVUX0o3Y2N6WEdKM1pyNXowZFRGbHIxenQxSlFJdjVNUHRYaWdrVGQ2TWNGR2dqaEpRaThPTDBKMWYtSThEZlVXalA2Vy1kUkFfYlE0RnppOEtScFMyUQ?oc=5","date":"2021-01-17","type":"pipeline","source":"MarketBeat","summary":"Top Lexaria Bioscience (LEXX) Competitors 2026 - MarketBeat","headline":"Top Lexaria Bioscience (LEXX) Competitors 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9kNHB4dHdlSGdGRXNQS0M2eTFFRU83XzV6cGxkQVZPU18wRWhwN2RYNWpMdEtRM0hLMmg1MHgwUTd0TlhVRkdyU1BzNkRkM3cwRFhiQmpPMjR6TnNkY2xfWmE0bFotYWtySHNEVGtKcUxDRkpWcjZFbWZvWklWdw?oc=5","date":"2020-09-21","type":"pipeline","source":"MarketBeat","summary":"Top NanoViricides (NNVC) Competitors 2026 - MarketBeat","headline":"Top NanoViricides (NNVC) Competitors 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQSHN2SGY5WXg0QXQ4MUEyODJZOW1VaWpiRlFaSEZ3MERZSVBSWnE1U2paT0taa1hrb1R6ZjRWdGgzQUJDay1iVTdCakU0NDFudi1fQXFFTnMxLWxtTmIxVmxBV3U4NUVpUUZzOEhmOWM0MnExRUVjdHBLalNncHc5bkdrRjZHekQyQXB3WmFiRm5ZQ20teU1tUGxkdWVHRlVOalhDMjhB?oc=5","date":"2020-02-10","type":"deal","source":"The Business Journals","summary":"$1.35B deal offers vindication, runway for Austin-based XBiotech - The Business Journals","headline":"$1.35B deal offers vindication, runway for Austin-based XBiotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE1wcXZqOWgzTFZYSVBGYVJmbm8zUXZWY0YwUjNlSWNsRkF2SnNEcFJNRU5aTUs3Z3dYZ2d0a0hKaUp6RnhxaU9ONjBpTEFxNkpnTy1fV1dNYURJUQ?oc=5","date":"2016-08-14","type":"pipeline","source":"MarketBeat","summary":"XBiotech (XBIT) Stock Price, News & Analysis $XBIT - MarketBeat","headline":"XBiotech (XBIT) Stock Price, News & Analysis $XBIT","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron Pharmaceuticals","Pfizer","Eli Lilly and Company"],"therapeuticFocus":["Immunology","Dermatology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":0,"grossProfitHistory":[],"rdSpend":47390000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-45540000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":125551000,"cashHistory":[],"totalAssets":150082000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}